{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lopes N"],"funding":["Fundação para a Ciência e a Tecnologia","Instituto Português de Oncologia do Porto"],"pagination":["102"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11297794"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["<h4>Background</h4>Oesophageal cancer remains a challenging disease with high mortality rates and few therapeutic options. In view of these difficulties, epigenetic drugs have emerged as potential alternatives for patient care. The goal of this study was to evaluate the effect and biological consequences of Panobinostat treatment, an HDAC (histone deacetylase) inhibitor already approved for treatment of patients with multiple myeloma, in oesophageal cell lines of normal and malignant origin, with the latter being representative of the two main histological subtypes: adenocarcinoma and squamous cell carcinoma.<h4>Results</h4>Panobinostat treatment inhibited growth and hindered proliferation, colony formation and invasion of oesophageal cancer cells. Considering HDAC tissue expression, HDAC1"],"journal":["Clinical epigenetics"],"pubmed_title":["Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines."],"pmcid":["PMC11297794"],"funding_grant_id":["CI-IPOP/PD/Kymab","CEECINST/00091/2018","10.544999/SFRH/BD/143717/2019","UID/DTP/0076/POCI-01-0145-FEDER-006868","CI‐IPOP/PD/Kymab","BF.CBEG CI-IPOP- 27-2016","UIDP/00776/2020"],"pubmed_authors":["Henrique R","Lopes N","Miranda-Goncalves V","Gigliano D","Guimaraes R","Correia MP","Jeronimo C","Salta S","Flores BT"],"additional_accession":[]},"is_claimable":false,"name":"Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines.","description":"<h4>Background</h4>Oesophageal cancer remains a challenging disease with high mortality rates and few therapeutic options. In view of these difficulties, epigenetic drugs have emerged as potential alternatives for patient care. The goal of this study was to evaluate the effect and biological consequences of Panobinostat treatment, an HDAC (histone deacetylase) inhibitor already approved for treatment of patients with multiple myeloma, in oesophageal cell lines of normal and malignant origin, with the latter being representative of the two main histological subtypes: adenocarcinoma and squamous cell carcinoma.<h4>Results</h4>Panobinostat treatment inhibited growth and hindered proliferation, colony formation and invasion of oesophageal cancer cells. Considering HDAC tissue expression, HDAC1","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-22T21:45:42.572Z","creation":"2025-04-06T03:46:26.902Z"},"accession":"S-EPMC11297794","cross_references":{"pubmed":["39097736"],"doi":["10.1186/s13148-024-01700-3"]}}